A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 [tipifarnib] in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2012
At a glance
- Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 21 Sep 2005 New trial record.